Navigation Links
Sunesis Pharmaceuticals Reports New Option Grants Under NASDAQ Marketplace Rule 4350
Date:10/4/2007

SOUTH SAN FRANCISCO, Calif., Oct. 4 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced the grant of employment inducement stock options awards in accordance with NASDAQ Marketplace Rule 4350 to two new non-executive employees.

The inducement stock options cover an aggregate of 48,000 shares of common stock and are classified as non-qualified stock options with an exercise price equal to the fair market value of Sunesis' common stock at the close of the trading day on the grant date. These stock options were approved by the Compensation Committee of Sunesis' Board of Directors. The options have a ten-year term and, subject to the terms and conditions of Sunesis' 2006 Employment Commencement Incentive Plan, vest over four years as follows: 25% of the shares subject to each option will vest on the one year anniversary of the grant date of each option; and the remaining 75% of the shares subject to each option will vest in 36 equal monthly increments during each of the second, third and fourth years thereafter.

Pursuant to NASDAQ Marketplace Rule 4350 (i)(1)(A)(iv), the options were granted on September 28, 2007 under Sunesis' 2006 Employment Commencement Incentive Plan, which Sunesis' Board of Directors adopted to facilitate the granting of stock options as an inducement to new employees to join Sunesis. In accordance with NASDAQ rules, these grants of stock options were made under a stock option plan without stockholder approval. NASDAQ rules require public announcement of option grants made under this type of plan.

About Sunesis Pharmaceuticals

Sunesis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics for oncology and other serious diseases. Sunesis has built a broad product candidate portfolio through internal discovery and in-licensing of novel cancer therapeutics. Sunesis is advancing its product candidates through in-house research and development efforts and strategic collaborations with leading pharmaceutical and biopharmaceutical companies. For additional information on Sunesis Pharmaceuticals, please visit http://www.sunesis.com.


'/>"/>
SOURCE Sunesis Pharmaceuticals
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Supply of Radiopharmaceuticals Hampered by Attacks
2. FDA approves Watson Pharmaceuticals Oxytrol patch
3. Ranbaxy Pharmaceuticals Inc awarded the prestigious outstanding supplier award received from Wal-Mart
4. Antigenics Pharmaceuticals plans for Phase III trial of its Melanoma vaccine
5. United Kingdom Is Lagging In Novelty In The Field Of Pharmaceuticals
6. Top Pharmaceuticals Influence Doctors Prescriptions
7. More Study On Side Effects of ADHD Drug Needed: Shire Pharmaceuticals
8. Personalized Medicine and Innovative Pharmaceuticals
9. New lease of life for asthmatics by Accentia Biopharmaceuticals
10. Pravastatin Launched by Watson Pharmaceuticals
11. Tata Industries picks up stake in Indigene Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... ... February 24, 2017 , ... Yisrayl Hawkins, Pastor and ... Bible Prophecy concerning this present generation. Yisrayl makes an astounding statement when he ... He explains that the Bible details the current times so plainly that anyone ...
(Date:2/24/2017)... ... , ... Indiana Fiber Network (IFN) President and CEO Kelly C. Dyer recently ... as the Chairman of the Management Committee when IFN was originally formed in 2002 ... of investor/owners and development of the business plan. He became the first paid ...
(Date:2/24/2017)... (PRWEB) , ... February 24, 2017 , ... ... marketing services, which specializes in thought leadership , media relations, social media, ... and services that will be powered through Act-On, an intuitive marketing automation platform. ...
(Date:2/24/2017)... ... February 24, 2017 , ... ... again hosted their Military Wedding Giveaway, with the winning couple announced on Feb. ... with services generously donated from local vendors: A Matter of Taste, Ryan Rousseau ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... jointly issued a letter to withdraw previous guidance issued by the ... identity. The guidance issued in May 2016 by the Obama Administration came in ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... Südkorea, 23. Februar 2017 LG Innotek hat ... vorgestellt. Die Sterilisationsleistung beträgt das 1,5-fache des 45-mW-Moduls der ... im Bereich zwischen 200 und 280 nm und eignet sich ... indem es ihre DNA zerstört. Das Produkt von LG ... ...
(Date:2/23/2017)... ITL Limited, ( ASX: ITD ), an innovative diversified healthcare company, ... 31 December 2016 compared with the previous corresponding period. A full ... here . Highlights Profit ... Earnings per share of 2.2 cents (Dec 2015: 1.2 cents; ... up 11%) Profit before tax of $2.12m (Dec ...
(Date:2/23/2017)... -- Research and Markets has announced the addition of the ... their offering. ... research Menopause Drugs Price Analysis and Strategies - 2016, provides drug pricing ... the following questions: What are the key ... in the Global Menopause market? What are the unit ...
Breaking Medicine Technology: